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ABSTRACT 
Description The purpose of this clinical practice update review is to describe 
key principles in the diagnosis and management of functional 
gastrointestinal (GI) symptoms in patients with inflammatory 
bowel disease (IBD). 
Methods The evidence and best practices summarized in this manuscript are 
based on relevant scientific publications, systematic reviews, and 
expert opinion where applicable. 
Best practice advice 1 A stepwise approach to rule-out ongoing inflammatory activity 
should be followed in IBD patients with persistent GI symptoms 
(measurement of fecal calprotectin, endoscopy with biopsy, cross-
sectional imaging). 
Best practice advice 2 In those patients with indeterminate fecal calprotectin levels and 
mild symptoms, clinicians may consider serial calprotectin 
monitoring to facilitate anticipatory management. 
Best practice advice 3 Anatomic abnormalities or structural complications should be 
considered in patients with obstructive symptoms including 
abdominal distention, pain, nausea and vomiting, obstipation or 
constipation. 
Best practice advice 4 Alternative pathophysiologic mechanisms should be considered 
and evaluated (small intestinal bacterial overgrowth, bile acid 
diarrhea, carbohydrate intolerance, chronic pancreatitis) based on 
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predominant symptom patterns. 
Best practice advice 5 A low FODMAP diet may be offered for management of functional 
GI symptoms in IBD with careful attention to nutritional adequacy. 
Best practice advice 6 Psychological therapies (cognitive behavioural therapy, 
hypnotherapy, mindfulness therapy) should be considered in IBD 
patients with functional symptoms. 
Best practice advice 7 Osmotic and stimulant laxative should be offered to IBD patients 
with chronic constipation. 
Best practice advice 8 Hypomotility agents or bile-acid sequestrants may be used for 
chronic diarrhea in quiescent IBD. 
Best practice advice 9 Antispasmodics, neuropathic-directed agents, and anti-depressants 
should be used for functional pain in IBD while use of opiates 
should be avoided. 
Best practice advice 10 Probiotics may be considered for treatment of functional symptoms 
in IBD. 
Best practice advice 11 Pelvic floor therapy should be offered to IBD patients with 
evidence of an underlying defecatory disorder. 
Best practice advice 12 Until further evidence is available, fecal microbiota transplant 
should not be offered for treatment of functional GI symptoms in 
IBD. 
Best practice advice 13 Physical exercise should be encourage in IBD patients with 
functional GI symptoms. 
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Best practice advice 14 Until further evidence is available, complementary and alternative 
therapies should not be routinely offered for functional symptoms 
in IBD. 
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INTRODUCTION  
Functional bowel disorders such as irritable bowel syndrome (IBS) are usually diagnosed 
based on symptoms that may overlap with those associated with inflammatory bowel disease 
(IBD). Distinguishing symptoms of this origin from those driven by persistent pathological 
changes associated with IBD such as inflammation or fibrosis may be challenging. A disconnect 
between symptoms and degree of intestinal inflammation has been well documented in Crohn’s 
disease (CD)1 while imaging studies and endoscopic and histologic evaluation to assess IBD 
activity may not be not definitive in separating these two etiologies of symptoms. The evidence 
to guide diagnostic and therapeutic strategies is thus often limited for functional gastrointestinal 
(GI) symptoms in IBD patients, but may involve one or more approaches, taking into 
consideration the unique circumstances of the individual.  This is critical, as overtreatment of 
intestinal inflammation for symptoms due to functional pathophysiology may increase the risk of 
significant adverse side effects while providing the patient with no symptomatic benefit.  Further 
guidance for clinicians is needed in improving clinical care and outcomes for IBD patients with 
coexisting functional GI symptoms as there are questions surrounding this patient population 
including:  
1) What steps should be taken when attempting to differentiate symptoms driven by 
underlying IBD from those related to functional pathophysiology? 
2) What other pathophysiologic mechanisms beyond active inflammation should we 
consider and investigate?  
3) What are they key principles in management of IBD patients with overlapping 
functional GI symptoms? 
While a true diagnosis of IBS or other functional GI disorders using established 
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diagnostic criteria such as the Rome IV criteria cannot be strictly applied to IBD patients, 
addressing functional pathophysiology is important. The current Clinical Practice Update Expert 
Review will discuss evaluation and management of functional GI symptoms in patients with IBD 
using available evidence and expert opinion. 
 
FUNCTIONAL GI SYMPTOMS IN IBD: PREVALENCE AND CONSEQUENCES 
The frequency of functional GI disorders in IBD varies depending on studied populations 
and diagnostic criteria used. For example, data from a meta-analysis indicated that the pooled 
prevalence for ‘IBS’ in all IBD patients from four case control and nine cross-sectional studies 
was 39% (95% CI 30-48%), with an OR compared to controls of 4.89 (95% CI 3.43-6.98) and a 
higher frequency in patients with CD than in those with ulcerative colitis (UC): 46 vs. 36%, OR 
1.62; 95% CI 1.21-2.18)2. In the included studies, ‘IBS’ was defined by diagnostic criteria 
(Manning, Rome I, Rome II, or Rome III) or any other validated GI symptom questionnaire and 
quality assessment of the four case control studies was low. Thus, the aforementioned numbers 
should be taken with caution. In addition, the presence of ongoing symptoms requires the careful 
exclusion of active inflammatory disease when initial evaluation suggests quiescent disease. In 
UC, for example, only 29% and 41% of patients who achieved a Mayo endoscopy subscore of 0 
reported a normal stool frequency 8 and 52 weeks after starting therapy, respectively3. However, 
a substantial proportion of these patients had evidence of persistent histologic inflammation on 
biopsy despite endoscopic remission. Still, it was subsequently reported that up to 27% of UC 
patients with both endoscopic and histologic healing may have increased stool frequency4. These 
data highlight the challenge of defining the true prevalence of functional GI symptoms in IBD. 
Studies also suggest a role for mechanisms5 not directly attributable to gut inflammation such as: 
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small intestinal bacterial overgrowth (SIBO)6, bile acid diarrhea (BAD)7, bowel damage from 
chronic inflammation; functional changes in motility or absorptive capacity; abnormalities in the 
enteric nervous system8; presence of intestinal dysbiosis9; or increased intestinal permeability10. 
It is interesting to note that many of these non-inflammatory mechanisms, which may be a 
consequence of prior chronic inflammation, have also been implicated in the multifactorial 
pathogenesis of functional GI disorders (FGID) and further investigation of such mechanisms in 
IBD is needed.  
Although the debate as to whether persistent symptoms in the presence of apparent 
mucosal healing are a consequence of coexisting functional disease has been described as 
irrelevant by some authors11, understanding their origin and how they can be treated is not since 
they consistently affect the quality of life (QOL) of patients. A longitudinal study examining the 
impact of persistent GI symptoms in 360 IBD patients found higher anxiety, depression and 
somatization scores, and lower QOL scores in IBD patients with GI symptoms compared to 
those with quiescent disease but without persistent symptoms12. Others have shown similar 
findings, demonstrating anxiety and reduced vitality to be independent predictors for functional 
symptoms among IBD patients in remission13. In a study from CCFA Partners, a diagnosis of 
“IBS” in IBD was associated with higher narcotic use compared with those without an ‘IBS’ 
diagnosis for both CD ([17% versus 11% (P < 0.001)] and UC/indeterminate colitis [9% versus 
5% (P < 0.001)]. Quality of life, as measured by the Short Inflammatory Bowel Disease 
Questionnaire (SIBDQ) was lower in patients with a FGID diagnosis compared with those 
without, and was associated with anxiety, depression, fatigue, sleep disturbances, pain 
interference and decreased social satisfaction14. Naliboff et al.15 also examined the 
interrelationships between GI symptoms, psychological distress, and health-related QOL in IBD, 
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IBS, and health. In this study, psychological distress was found to be more dependent on GI 
symptoms in IBD compared to IBS although significant effects of psychological distress on 
health-related QOL between groups were similar. 
Finally, an inability to reliably distinguish functional GI symptoms from IBD has 
obfuscated results of clinical trials in the past. It has been shown that the CDAI, a commonly 
used objective end-point criterion, may be as high in IBS as in IBD patients. The most 
compelling evidence regarding this confusion came from the SONIC trial; where there was no 
difference between treatment arms for patients included based on CDAI only and no objective 
inflammation1. Since then, measurement of increased clinical and objective activity [either based 
on endoscopy and/or inflammatory biomarkers such as C-reactive protein (CRP) and/or 
calprotectin] is a prerequisite for inclusion in clinical trials. Similarly, in clinical practice, no 
therapeutic decision should be taken based on clinical consideration alone. 
 
HOW CAN WE IDENTIFY FUNCTIONAL GI SYMPTOMS IN PATIENTS WITH IBD?  
Clinical assessment 
Evaluation of persistent symptoms in the IBD patient should begin with a detailed 
symptom history including a review of bowel patterns taking into account the clinical spectrum 
of patient presentations as symptom severity may not always directly correlate to degree of 
inflammatory activity (Supplemental Figure 1). Clinicians should query patients on presence and 
severity of the following: associated pain, incontinence episodes, urgency or tenesmus; alarm 
features (e.g. weight loss, nocturnal symptoms, bleeding, high volume or high frequency 
diarrhea, fevers); recent antibiotic-use; and symptom duration to identify features that may point 
away from a functional etiology. Presence of alarm features or acute symptom onset in patients 
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with previously well-controlled disease should prompt the clinician to maintain a high index of 
suspicion for underlying inflammatory activity. Physical examination should assess for objective 
findings suggesting organic pathology or active IBD such as abdominal distension or masses. 
Careful rectal examination should inspect for perianal or anorectal disease. In those without 
obvious perianal pathology to explain symptoms, a digital rectal exam to palpate for mass lesions 
and to screen for a rectal evacuation disorder16 should be completed. 
Evaluate for ongoing inflammation 
Objective evidence of inflammatory activity based on laboratory testing such as serum 
CRP and fecal calprotectin (FC) should be addressed. However, the use of noninvasive 
biomarkers has important limitations. CRP, an acute phase reactant, has shown poor sensitivity 
and up to 15% of patients may fail to mount a CRP response17. Discerning optimal cutoffs for 
biomarkers remains a source of debate. In one retrospective review, FC levels < 60 µg/g were 
found to be predictive of deep remission in ulcerative colitis (UC) patients with 86% sensitivity 
and 87% specificity18 while a prior prospective study reported FC levels  < 40.5 µg/g to be 
predictive of histological remission with 41% sensitivity and 100% specificity19. Thresholds for 
fecal calprotectin in the range of 200-250µg/g may predict endoscopic remission in both UC and 
CD20, 21. Thus, while FC values < 50 µg/g may be reassuring and point the clinician towards 
consideration of a non-IBD etiology for persisting symptoms, values between 50 and 250µg/g 
may be challenging to interpret as upper normal limits may vary and mild calprotectin elevation 
may be seen with non-specific low grade inflammation22. In those with mild symptoms, serial 
calprotectin monitoring at three to six months intervals may be appropriate to facilitate early 
recognition with treatment of impending disease flares23. If a flare is suspected, endoscopy with 
biopsies and/or dedicated imaging of the small bowel in CD patients should be considered. As 
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previously mentioned, the potential for persistent histological and/or transmural inflammation 
even with endoscopic evidence of mucosal healing cannot go unnoticed. The role of histology 
and cross-sectional imaging as a therapeutic target requires further study, particularly as they 
may reflect inflammatory mechanisms driving refractory symptoms or leading to clinical relapse. 
Anatomic abnormalities and other considerations in IBD  
Active small bowel CD and complications such as stenosis and fistulas can be missed if 
the diagnosis is only made through ileocolonoscopy without systematic cross-sectional imaging 
of the small bowel24. Fibrostenotic disease from chronic inflammation or surgical sequelae such 
as ischemic strictures and adhesions leading to obstructive symptoms25 of abdominal pain, 
nausea and vomiting, distention, or obstipation or constipation from fecal stasis in uninflamed 
colon proximal to distal colitis26, 27. Further, although UC is traditionally thought of as a disease 
limited to the mucosa and superficial submucosa, mounting (and forgotten) evidence supports 
the existence of transmural chronic inflammation. This results in a thickening of the muscularis 
mucosa and increased collagen deposition compared with healthy control subjects. Accumulating 
data support the notion that fibrosis is a common occurrence in UC28. It affects the mucosa, 
submucosa, and in some instances, the muscularis propria and even subserosa, in particular in 
cases of deep ulceration. These fibrotic changes are likely to have important clinical 
consequences through effects on colonic motility and anorectal function, even in the absence of 
strictures or active mucosal disease29. As nicely summarized in a recent editorial, it is time in UC 
to “look underneath the surface” in developing new therapeutic interventions in IBD30 which 
may involve the future use of novel anti-fibrotics as explored in CD. 
Investigating pathophysiologic mechanisms beyond inflammation 
When objective evidence of active inflammation or IBD-specific mechanisms is 
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insufficient to account for the nature of the persistent symptoms in IBD, alternative pathogenic 
mechanisms should be considered and addressed before attributing symptoms to functional GI 
symptoms. Several pathophysiological perturbations may contribute to GI symptoms in patients 
with IBD. These pathophysiologic mechanisms, may at times be uniquely associated with the 
IBD patient, but in many cases may overlap with pathways that have been implicated in 
pathophysiology of functional disorders. Subsequent testing should be guided by predominant 
symptom patterns.  
Steatorrhea and chronic abdominal pain may occur as a consequence of PEI or chronic 
pancreatitis which may complicate IBD31. Evidence suggests an increased prevalence of PEI in 
IBD (OR=10.5, 95% CI 2.5-44.8) vs. controls based on screening by fecal elastase, though it 
should be kept in mind that falsely low fecal elastase may be secondary to diarrhea32 and the 
clinical significance of PEI in IBD remains undefined. BAD may not only be important in CD 
patients with ileal disease, but is also a common cause of functional diarrhea or diarrhea-
predominant IBS33. Several diagnostic tests to screen for BAD are now available33 including 
assessment of 48 hour fecal bile acid excretion, which has demonstrated reasonable diagnostic 
yield compared to 75SeHCAT retention, a test that is not widely available in most countries. 
Serological testing of serum C4 and FGF19 may represent practical diagnostic tools for BAD, 
although further clinical validation is required. 
Structural changes and alterations in motility or gut defenses predisposing IBD patients to 
SIBO may result in abdominal pain, diarrhea, bloating or other nonspecific GI symptoms. SIBO 
in CD is common, occurring in up to 30%34. It may be particularly important in those with 
stricturing6 or fistulizing phenotype35 and may be associated with hypomotility or loss of the 
ileocecal valve36. In UC, the reported prevalence of SIBO is lower and its role in producing 
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symptoms less clear37. Though SIBO has traditionally been defined as positive bacterial cultures 
from small bowel aspirates, many experts have deemed small bowel culture to be unsatisfactory 
for diagnosis due to inherent limitations such as possible contamination by oropharyngeal flora, 
inaccessibility of the small bowel with potential for false negatives, and the invasive and costly 
nature of testing38. Thus, recent consensus guidelines have suggested hydrogen and methane-
based breath testing for SIBO using glucose or lactulose substrates until validated gold standards 
for testing are established. Reported sensitivity and specificity of glucose breath testing has 
ranged from 20-93% and 30-86% respectively, while sensitivity and specificity of lactulose 
hydrogen breath testing has ranged from 31 to 68% and 44 to 100%38. Some have suggested that 
that lactulose breath testing be avoided due to effects on small bowel transit and concerns of its 
sensitivity and specificity39. It should, however, be noted that the effect of rapid small intestinal 
transit in patients with IBS has cast doubt upon some of the indices claimed to be diagnostic of 
SIBO, whether lactulose or glucose is used as the substrate40. For some patients, the suspicion of 
bacterial overgrowth may be high enough that empiric therapy is indicated. 
Breath testing following these same consensus guidelines38 to evaluate for carbohydrate 
malabsorption leading to diarrhea, bloating, and flatulence may provide additional opportunities 
for intervention. In one study, lactose malabsorption was twice as frequent in UC and CD 
compared to in healthy controls and patients with FGID41, 42. Fructose malabsorption has been 
shown to be more frequent in CD than in comparator groups by hydrogen breath testing 
unrelated to small intestinal transit, intestinal resection or SIBO41.  
Enhanced visceral sensitivity may be considered, particularly in those with pain, although 
data to support this effect in IBD are conflicting. In a study comparing 19 patients with quiescent 
UC and 17 controls, van Hoboken et al. demonstrated increased visceroperception by rectal 
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barostat among UC patients in remission43 in addition to a weak but significant correlation 
between perception and the number of mucosal mast cells. However, a previous investigation of 
patients with UC reported rectal sensitivity to be decreased during remission and not 
significantly different between those with quiescent colitis and controls to suggest that visceral 
hypersensitivity was unlikely to be explained by permanent scarring or sensitization44.  
Other special considerations may include intestinal barrier dysfunction even with 
endoscopic evidence of mucosal healing. Intestinal permeability as a therapeutic targets or as a 
marker for genetic predisposition for impaired barrier function in IBD requires further 
investigation45. In a recent study, persistent symptoms of diarrhea and abdominal pain were 
reported in 16.3% of IBD patients despite mucosal healing and were associated with increased 
intestinal permeability10, suggesting a role for targeting recovery of the intestinal barrier in IBD 
as an endpoint for control of persistent gut symptoms.  
Functional gastrointestinal symptoms in IBD 
If symptoms should persist despite lack of objective inflammation and appropriate 
management of alternative etiologies, consideration can be given for overlapping functional GI 
symptoms. Indeed, both FGID and IBD may share many common pathophysiologic disturbances 
that in some IBD patients may be a consequence of prior structural and functional bowel 
damage4. Exploration of IBS symptoms may include testing to rule-out pelvic floor disorders 
with anorectal manometry and balloon expulsion test in those with chronic constipation, fecal 
incontinence, overflow diarrhea or other defecatory disorders as these conditions may respond to 
biofeedback therapy46. Psychiatric or psychological disturbances are associated with IBS-like 
symptoms in IBD while anxiety and reduced vitality have been shown to independently predict 
IBS-like symptoms 13. 
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All aforementioned non-inflammatory perturbations, together with potential investigative 
approaches, are outlined in the Table 1. Hence, as in patients with FGID, multiple pathogenic 
pathways may be relevant in patients with IBD, especially when designing a therapeutic 
approach. 
 
HOW CAN WE TREAT FUNCTIONAL GI SYMPTOMS IN PATIENTS WITH IBD? 
There is a paucity of randomized controlled trials or even prospective studies that have 
examined the impact of therapy for functional GI symptoms in patients with IBD. However, non-
pharmacological therapies with efficacy in IBS and other FGID as well as pharmacological 
interventions are often applied in clinical practice. As mild residual inflammation and functional 
GI symptoms can co-exist, therapy of inflammation and functional symptoms are not mutually 
exclusive. Therapeutic decisions for the functional symptoms are largely made on an empiric 
basis, being borrowed from those in patients with IBS and other FGID, and might span dietary, 
psychological, pharmacological, and other therapies. Attention has to be paid to 
pathophysiological mechanisms that might offer opportunities for specific therapies as outlined 
in Tables 1 and 2.  
Dietary therapy 
Several dietary approaches appear to be associated with improved functional GI 
symptoms in IBD patients, including lactose-reduced, FODMAP-reduced, gluten-free and 
specific-carbohydrate diets. The common denominator for improved symptoms in all of these 
approaches is the reduced intake of indigestible and slowly absorbed carbohydrates that may 
induce symptoms through luminal distension and mechanoreceptor stimulation by virtue of their 
osmotic effects and fermentability. This is the basis for the lactose-reduced diet in patients with 
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lactose malabsorption and the low FODMAP diet in which all short-chain carbohydrates are 
reduced. Indeed, in a randomized controlled feeding study in a small cohort of CD patients, 
typical FODMAP intake was associated with increased symptom severity47. Other studies have 
shown benefit with a reduced FODMAP diet in at least 50% of IBD patients with ongoing 
symptoms despite controlled inflammatory disease48. A blinded re-challenge study confirmed 
that FODMAPs are a likely dietary culprits for functional symptoms in patient with quiescent 
IBD49.  
For gluten-free diet, there is currently no evidence that gluten or wheat protein is the 
culprit dietary component in more than a small minority of IBS patients. Observational and 
blinded re-challenge studies indicate that concomitant reduction in FODMAP intake is the likely 
mechanism, especially as fructans co-exist with gluten in cereals50. In a recent double-blind 
cross-over challenge among patients with self-reported non-celiac sensitivity, overall symptoms 
as assessed by the GI symptom Rating Scale IBS version, were significantly higher for those 
consuming fructans than those consume gluten51. Whether the same applies to patients with IBD 
has not been examined, but at least one in four patients in both UK and US surveys have found 
that a gluten-free diet can provide symptomatic relief prompting 6-8% of patients to remain 
gluten-free48. There are no completed randomized studies.   
Restrictive diets are not without potential adverse effects. In conditions where 
undernutrition is common, such as IBD, attention to nutritional adequacy in the face of dietary 
restriction is essential; and dietary instruction should be delivered by a dietitian. The effects of 
reducing carbohydrates with prebiotic actions might have deleterious effects on the gut 
microbiota. However, a feeding study in which FODMAPs were strictly controlled in CD 
patients did not alter the relative abundance of a limited number of key bacteria with functional 
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significance compared with microbiota associated with the patient’s habitual diet47. More real-
world data are required.  Finally, while certain diets are proposed to reduce inflammation, others 
may potentially do the opposite. Such information needs careful study.  
Psychological therapy 
Several psychological techniques, such as cognitive behaviour therapy, gut-directed 
hypnotherapy, mindfulness therapy and psychodynamic psychotherapy have strong evidence of 
efficacy for abdominal symptoms in patients with IBS52. The evidence-base for benefits of such 
techniques in patients with IBD is less compelling and most studies have addressed coping skills, 
anxiety, and depression rather than abdominal symptoms or inflammatory activity52, although 
novel approaches with incorporation of positive psychogastroenterology has shown promise53. 
The high prevalence of psychological co-morbidities in patients with IBD gives greater impetus 
to try psychological strategies in patients with functional GI symptoms and IBD, particularly in 
light of existing data to suggest that GI symptoms may be more directly linked to psychological 
distress affecting health-related QOL in IBD than in IBS alone15. 
Pharmacological therapy 
Few high-quality studies have directed attention towards the use of pharmacotherapy in 
relieving functional GI symptoms in patients with IBD, yet pharmacotherapy is commonly 
applied. Therapies are generally directed towards relief of specific symptoms: laxatives and/or 
pro-kinetic agents are applied in chronic constipation, particularly in association with distal UC; 
hypo-motility agents or anti-diarrheals such as loperamide, bile-acid sequestrants for presumed 
BAD, and pancreatic enzyme replacement therapy for presumed PEI may be used for chronic 
diarrhea; antispasmodics or neuropathic-directed analgesia may be used for chronic pain; 
antidepressant and anxiolytic medication for abdominal symptoms as well as for anxiety or 
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depression. One retrospective cohort study in 81 IBD patients with functional GI symptoms 
demonstrated that tricyclic antidepressants leads to a clinically relevant benefit for symptoms54. 
The use of opiates should be avoided for management of chronic abdominal pain in general, and 
particularly in patients with IBS symptoms after remission of acute inflammation. Widespread 
use of opiates in clinical practice for non-cancer pain has been tied to increasing risk of overdose 
and may contribute to opioid-induced GI side effects55. The study of novel agents for the 
treatment of visceral pain such as APB371, a cannabinoid receptor type 2 agonist is currently 
underway in phase 2 clinical trials in CD56. The application of other newer IBS-related therapies 
in patients with IBD has yet to be reported.  
Manipulating the gut microbiota 
Antibiotics such as rifaximin are often applied for presumed SIBO, but formal evaluation 
for this indication in IBD remains limited to a small randomized study of 14 CD patients with 
inactive ileal disease and breath-test diagnosed overgrowth SIBO. In this study, all seven patients 
randomized to rifaximin had a negative follow-up breath test, while only two of seven 
randomized to placebo achieved this response57. In IBD patients with active luminal disease, 
there has been evidence suggesting rifaximin to be effective in inducing58, 59and maintaining60 
remission in CD while limited older data in steroid-refractory UC has demonstrated benefit over 
placebo61. Rifaximin has demonstrated efficacy in relieving IBS symptoms of bloating, 
abdominal pain, and loose or watery stools among patients with non-constipation predominant 
IBS in multiple controlled clinical trials, and is approved for the treatment of diarrhea-
predominant IBS62. A recent study showed modest changes in microbial richness with rifaximin 
treatment in IBS. However, the exact mechanism by which rifaximin exerts its beneficial effects 
– whether by changing gut microbiota in general or by reducing SIBO - remain uncertain.63 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
Moreover, in a recent cross-sectional analysis, no association was observed between IBS 
symptoms and microbiome alterations among patients with IBD although effects of confounding 
could not be excluded64. Probiotics have been widely studied for functional GI symptoms with 
variable success, though the increments of benefit are often small. Efficacy for such symptoms in 
patients with IBD has not been evaluated. Fecal microbiota transplantation has been directed 
towards mucosal inflammation rather than functional symptoms.  
Pelvic floor therapy 
The application of pelvic floor therapy targeting dyssynergic defecation has shown 
gratifying benefit in many patients with IBS and constipation. In a study of 30 patients with IBD 
in remission and defecatory disorders, 30% had clinically relevant benefit from biofeedback 
therapy46 The potential for such an approach in those with functional symptoms requires greater 
exploration. 
Complementary and alternative medicine 
The application of complementary and alternative medicine (CAM) and functional foods 
to patients with in IBD has been recently reviewed65, but studies have not been directed 
specifically at functional GI symptoms. For example, marijuana may reduce symptoms in IBD, 
but does not clearly alter disease course based on objective assessment of disease activity. 
Curcumin has been associated with induction and maintenance of remission in UC, although 
studies may have been inadequately blinded. Higher remission rates were also reported in one 
study with aloe vera in UC. Acupuncture and moxibustion were found to be superior to oral 
sulfasalazine in IBD. However, studies have generally been of low quality65.  
Physical exercise 
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Programs involving moderate exercise have in general, been shown to improve well-
being and to be safe in patients with quiescent or mildly active IBD without detectable benefit to 
inflammatory activity65. In a study using the CCFA Partners cohort, higher exercise levels were 
also found to be associated with decreased risk of active disease among CD patients in 
remission66. In IBS, physical activity has been shown to improve GI symptoms in a randomized 
clinical trial67. Whether exercise would be of benefit in patients with IBD and concomitant 
functional GI symptoms is untested. 
 
FUTURE DIRECTIONS 
While there appears to be increased recognition by clinicians that GI symptoms not fully 
derived from IBD commonly complicate the clinical picture in patients with IBD, better 
diagnostic evaluation is needed to further define the contribution of each to a patient’s 
symptoms. This may be assisted by identifying novel biomarkers for FGID and IBD 
incorporating approaches based on genetic, metabolomic, proteomic, and microbial pathways. 
Another important area of focus should include integration of bi-directional brain-gut pathways 
and studies on the role of stress or psychological health, which may have important implications 
for clinical presentation and non-inflammatory symptom management in patients with IBD68. In 
the future, therapeutic approaches that are not empiric, but based upon the results of well-
designed randomized controlled trials will greatly enhance the clinician’s ability to more 
effectively apply a personalized management plan for functional symptoms as well as therapy of 
the inflammation itself.
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Table 1: Acquired pathophysiological mechanisms that might potentially contribute to persistent gastrointestinal (GI) symptoms in 
patients with inflammatory bowel disease (IBD) and that might offer opportunities for therapy 
Potential pathophysiological abnormalities Presentation Potential investigations Potential therapy 
Inflammation-
associated 
abnormalities in 
GBA# 
Anxiety and depression Pain, IBS*, fatigue Psychological or 
psychiatric evaluations 
Psychological 
therapy, 
antidepressant, 
anxiolytic  
Hypervigilance, central sensitization 
of pain processing  
Pain, IBS Similar approaches 
as for IBS 
Altered visceral sensory neurons 
(‘neuroinflammation’) with structural, 
receptor and functional abnormalities; 
activation or sensitization of 
nociceptors; ↑mast cell density 
Pain, IBS  
Consequences of 
IBD due to 
changes in 
structure and/or 
function of GI 
tract 
Bile acid diarrhea Diarrhea, IBS 75SeHCAT testing**, 
fecal bile acids 
Bile salt sequestrant 
Small intestinal bacterial overgrowth Diarrhea, bloating, 
gas, pain, IBS 
Breath testing, culture of 
small bowel aspirates 
Antibiotics 
Pancreatic exocrine insufficiency31 Pain, weight loss, 
bloating, diarrhea 
Fecal elastase Pancreatic enzyme 
replacement  
Lactose or fructose malabsorption41 Gas, bloating, 
diarrhea, IBS 
Breath testing Dietary restriction 
 Obstipation or constipation from fecal 
stasis in uninflamed colon proximal to 
distal colitis (UC$)26,27 
Constipation Abdominal X-ray Laxation, prokinetic 
 Intestinal stenosis (CD@) Pain, obstruction  Imaging, endoscopy Dilatation, surgery 
 Pelvic floor dyssynergia46 Pain, constipation, 
IBS 
Rectal exam, anorectal 
physiological studies 
Biofeedback therapy 
Mechanisms not 
specifically 
Celiac disease Diarrhea, gas, 
malabsorption 
Celiac serology, small 
intestinal biopsy 
Gluten-free diet 
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associated with 
IBD 
#GBA=Gut brain axis. *IBS=Irritable bowel syndrome; Functional symptoms similar to IBS may be observed as a consequence of 
several of the aforementioned pathophysiologic abnormalities, many of which have been implicated as central and peripheral 
mechanisms in IBS pathogenesis. $UC=ulcerative colitis. @CD=Crohn’s disease. **75SeHCAT testing is not widely available in most 
countries outside of Europe or Canada 
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Table 2: Summary of therapies applicable to irritable bowel syndrome (IBS) or related disorders and inflammatory bowel disease 
(IBD) 
Therapy Intervention(s) Evidence for efficacy in 
IBS or related disorders 
Evidence for efficacy in 
IBD 
Overall interpretation 
Diet Low FODMAP*; GFD#  Evidence of benefit with 
↓FODMAP intake; GFD 
possibly helpful in subset 
of IBS69  
Evidence for benefit with 
↓FODMAP in CD$ and 
IBD49, 50; no randomized 
trials testing GFD in IBD  
Restrictive diet potentially 
helpful with consideration 
of nutritional adequacy. 
Further data required. 
Psychological 
therapy 
Cognitive behavioral 
therapy, hypnotherapy, 
mindfulness therapy 
Efficacy for abdominal 
symptoms, psychological 
distress52 
Limited evidence supports 
efficacy for anxiety and 
depression52 
Clinically valuable 
therapeutic option in IBD 
patients with functional 
symptoms 
Pharmacologic 
treatment for 
constipation 
PEG!, stimulant 
laxative, secretagogue, 
prokinetic (e.g. 5-HT4 
receptor agonists 
including tegaserod** 
and prucalopride^) 
PEG effective for 
constipation70; stimulants 
beneficial in CCα71; 
secretagogues approved 
for IBS-C and CC; 5-HT4 
receptor agonists effective 
for CC69 
Lack of clinical trial data 
examining specific effects of 
pharmacologic treatment for 
constipation in IBD 
Osmotic and stimulant 
laxatives generally safe 
and effective for treatment 
of constipation in IBD. 
Further data required on 
use of newer agents. 
Pharmacologic 
treatment for 
diarrhea 
Loperamide, 5-HT3 
antagonist (alosetron┼), 
bile acid sequestrant, 
mixed opioid 
agonist/antagonist 
(eluxadoline) 
Net benefit with 
loperamide72; alosetron 
improves IBS symptoms; 
bile acid sequestrants 
improve diarrhea; 
eluxadolineβ approved for 
IBS-D69 
Loperamide effective in 
CD73; bile acid sequestrants 
effective in CD with 
malabsorption74; no data on 
safety and efficacy of 
alosetron or eluxadoline 
Hypomotility agents and 
bile acid sequestrants can 
be used for diarrhea in 
IBD. Further study needed 
for newer agents. 
Pharmacologic 
treatment for 
pain, anxiety, 
depression 
Antispasmodic, anti-
depressant (tricyclic 
anti-depressant, SSRIγ) 
Antispasmodics75 and 
antidepressants effective 
in IBS76 
Tricyclics associated with 
benefit in IBD54 
Consider antispasmodics, 
neuropathic-directed 
agents, anti-depressants 
for functional pain in IBD 
Antibiotics Rifaximin Rifaximin approved for Rifaximin associated with Evidence for benefit,; 
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diarrhea-predominant 
IBS62 
negative breath test in CD57, 
induction and maintenance 
of remission in active CD, 
and benefit over placebo in 
steroid-refractory UCδ57 
however, indication for 
use in IBD and 
mechanisms by which 
rifaximin exerts its benefit 
are unclear 
Probiotics Multiple agents Variable success Efficacy for functional 
symptoms in IBD has not 
been evaluated 
Further data supporting 
use of probiotics for 
functional symptoms in 
IBD needed; however, 
risk of harm is low 
Pelvic floor 
therapy 
Biofeedback for 
dyssynergic defecation 
Beneficial for treatment of 
constipation with 
dyssynergia 
Benefit with biofeedback in 
30% IBD patients in 
remission with defecatory 
disorders46 
Potential for benefit; 
however, formal study is 
needed 
Physical 
exercise 
Exercise Exercise improves GI 
symptoms67  
Exercise beneficial in 
quiescent or mild IBD65  and 
associated with ↓risk of 
active disease66 
Likely beneficial with low 
risk of harm. No formal 
evaluation for functional 
symptoms in IBD reported 
Complementary 
alternative 
medicine 
(CAM) 
Herbal therapy, dietary 
supplements, 
acupuncture, 
moxibustion, yoga 
CAM such as herbal 
therapies and acupuncture 
potentially beneficial, but 
rigorous clinical trials 
lacking69 
Marijuana may reduce 
symptoms, but does not 
clearly alter disease course; 
Curcumin associated with 
induction and maintenance 
of remission in UC; Higher 
remission rates with aloe 
vera in UC; Acupuncture and 
moxibustion superior to oral 
sulfasalazine in IBD65  
Further research needed to 
validate CAM for 
functional symptoms in 
IBD 
*FODMAP = Fermentable oligosaccharides, disaccharides, monosaccharides and polyols; #GFD = Gluten-free diet; $CD = Crohn’s 
disease; !PEG = polyethylene glycol; **Tegaserod taken off market due to concern for possible cardiovascular events; ^prucalopride 
is not available in the United States; αCC = chronic constipation; ┼alosetron approved with restrictions for women with severe 
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diarrhea-predominant IBS in United States; βeluxadoline associated with increased risk of pancreatitis and should be used with 
careful monitoring following FDA prescribing information; γSSRI = selective serotonin reuptake inhibitor; δUC = ulcerative colitis  
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Suspicion	of	func+onal	gastrointes+nal	symptoms	
Clinical	assessment	
Laboratory	assessment	for	inflammatory	
markers	(e.g.,	CRP,	calprotec;n)	
Borderline	inflamma;on*		Unequivocal	inflamma;on*	 No	evidence	of	ac;ve	inflamma;on*	
Op;mize	an;-
inflammatory	therapy	
Endoscopic/histopathological	
&/or	imaging	assessment	
Symptoms	less	consistent	
with	degree	of	inflamma;on	
Ac;ve	inflammatory	
disease	
Non-inflammatory	(func;onal)	
symptoms	
Iden;fy	pathophysiological	contributors	
(Table	1)	
Treat	as	for	IBS	 Specific,	targeted	
therapy	(Table	1)	
Dietary	
therapy	
Psycho-
therapy	
Pharmaco-
therapy	
Physio-
therapy	*	Cut-off	values	for	inflammatory	markers	such	as	
calprotec9n	will	vary	according	to	the	clinical	scenario	
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